• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category

    3/5/24 9:06:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALNY alert in real time by email

    As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on the boards of several biotech and pharmaceutical companies; This marks ByHeart's first non-executive Board chair appointment

    In addition to Schulman, ByHeart appoints Niall Mullane, PhD, as Chief Quality Officer to join the experienced executive team; Mullane brings 15 years of quality and food safety experience in the infant nutrition category

    NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of the Board. A stalwart supporter of ByHeart since its inception, Schulman's designation signifies a pivotal moment for the company as it experiences momentous growth and solidifies its position as an industry leader.

    ByHeart Logo (PRNewsfoto/ByHeart)

    Schulman's support of ByHeart dates back to the early stages of the company's development, when she played a crucial role as one of the first institutional investors, with Polaris co-leading the series A funding round and participating in each additional round since. With a distinguished career that spans various roles at Pfizer, including President of Pfizer Nutrition and Pfizer Consumer Healthcare, Schulman brings a wealth of experience and expertise in infant formula and consumer health.

    "Amy's insights and passion for health innovation and social impact align with ByHeart's mission," said ByHeart Co-Founder and CEO Ron Belldegrun. "We chose Amy as the Chair because of her extensive track record in life sciences and infant nutrition. No one better understands what it takes to apply 21st century functional nutrition to revolutionize babies' first food and set a strong foundation for future health."

    In addition to her new role at ByHeart, Schulman also serves as Chair of the Board of Directors of Alnylam Pharmaceuticals (NASDAQ:ALNY) and as executive chair of Lyndra Therapeutics, where she was co-founder and the company's initial CEO. She is also a managing partner at Polaris Partners and Co-Founder of the Polaris Innovation Fund, serving on the firm's life sciences investment team and a senior lecturer at Harvard Business School. Her commitment to health also extends to her board appointments on the Boards of Action Against Hunger, Mount Sinai Hospital (where she co-chairs the Innovations Committee), and the California Institute of Technology. She is a member of Singapore's Health and Biomedical Sciences International Advisory Council and the LifeSci NYC Advisory Council.

    "I have been a staunch supporter of ByHeart from its early days, and I am honored to now chair their board," said Schulman. "The company takes a rare but much needed innovative, evidence-based approach to infant nutrition. This approach together with their unwavering commitment to quality and safety and dedication to making formula parents and babies love is setting a new standard. I look forward to working with the ByHeart team and the amazing founders on their journey to enhance the wellbeing of generations to come."

    "We're honored that Amy agreed to chair our board. She leads with integrity and a people-first commitment, while also always thoughtfully challenging the status quo and seeking ways to push the bounds of what's possible to drive health innovation," said Mia Funt, ByHeart Co-founder and President. "Also, on a personal note, she's an inspiring business woman and family woman, who welcomes open conversations about the daily choices we make between family and career. We need more female leaders like her to set an example for the next generation."

    ByHeart continues to build an impressive roster of talent with the addition of Niall Mullane, PhD, as Chief Quality Officer, joining the experienced executive team consisting of: Georg Krause-Vilmar, Chief Legal Officer; Bob Peruzzi, Chief Financial Officer; Elias Aoukar, Chief Operating Officer; Devon Kuehn, MD, Chief Medical Officer; Ron Belldegrun, CEO and Co-Founder; and Mia Funt, President and Co-Founder. Mullane is a global quality leader with over 15 years of experience working in the infant formula industry and brings unparalleled value to ByHeart's quality control and safety practices. He previously held senior quality and food safety positions with the industry's major players, Mead Johnson and Reckitt, in both their global and regional operational quality teams. With an extensive background in food safety oversight and as a microbiologist with a unique PhD specifically in Cronobacter, Mullane will play an integral role in managing the continued success of ByHeart's domestic supply chain and infrastructure. Alongside his distinctive industry experience, Mullane is fervently committed to upholding ByHeart – and the broader industry – to the highest global standards of quality for infant formula, the fundamental nutrition for babies worldwide.

    This announcement comes at a significant juncture for ByHeart, following the successful integration of two new manufacturing facilities, which solidified the company's ownership of its end-to-end manufacturing supply chain in the United States. ByHeart now boasts a full omnichannel presence with direct-to-consumer and retail offerings at Target both in-store and online, further positioning itself as a dynamic force within the infant formula market. ByHeart remains dedicated to advancing infant nutrition through science, innovation and a commitment to excellence.

    About ByHeart

    Founded in 2016 and based in New York City with manufacturing facilities in Pennsylvania, Oregon and Iowa, ByHeart is the baby nutrition company dedicated to empowering parents with choices for a better feeding future. ByHeart is only one of five fully integrated, FDA-registered infant formula brands in the country, and ByHeart facilities are driven by nutritional excellence and a farm-to-formula verified™ quality program. For more information on ByHeart, visit https://byheart.com/.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/byheart-appoints-amy-schulman-as-chair-of-the-board-of-directors-further-solidifying-its-position-as-a-leader-in-the-infant-nutrition-category-302080011.html

    SOURCE ByHeart

    Get the next $ALNY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALNY

    DatePrice TargetRatingAnalyst
    8/4/2025Underperform → Peer Perform
    Wolfe Research
    8/4/2025$490.00Perform → Outperform
    Oppenheimer
    7/30/2025$370.00Outperform
    Raymond James
    7/21/2025$385.00Buy
    Truist
    3/31/2025$353.00Buy
    Redburn Atlantic
    3/24/2025$280.00 → $328.00Neutral → Overweight
    Analyst
    11/12/2024Peer Perform → Underperform
    Wolfe Research
    10/16/2024Sector Outperform
    Scotiabank
    More analyst ratings

    $ALNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

    - Global Cardiovascular Outcomes Trial will Enroll ~11,000 Patients Across 35 Countries to Evaluate Zilebesiran as a Novel Biannual Treatment - - Trial to Assess Zilebesiran in Patients with Uncontrolled Hypertension with Either Established or at High Risk of Cardiovascular Disease - - Milestone Payment of $300 Million Triggered Under Global Collaboration and License Agreement with Partner Roche - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that the first patient has been dosed in ZENITH (ZilebEsiraN CardIovascular OuTcome Study in Hypertension), a global Phase 3 cardiovascular outcomes trial (CVOT) designed to evaluate the poten

    10/1/25 7:30:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

    − Treatment with Vutrisiran Led to 37- 49% Lower Rates of Gastrointestinal Events, a Multisystem Manifestation of ATTR-CM, Across Multiple Treatment Groups, Compared to Placebo – − Additional Analyses Reinforce Vutrisiran's Safety and Efficacy Profile as a Monotherapy and Illustrate Consistent Benefit from Treatment with Vutrisiran Across a Range of Patients' Baseline Health Status and Quality of Life – − Findings Presented at the Heart Failure Society of America Annual Scientific Meeting 2025 Highlight the Impact of Vutrisiran which Delivers Rapid Knockdown of Transthyretin – Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company, today announced results

    9/28/25 11:13:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

    Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD). Alnylam, a pioneer in RNA interference (RNAi) therapeutics, will utilize the AGD clinical genomic database to derive real-world insights and accelerate drug target discovery.

    9/18/25 9:15:00 AM ET
    $ALNY
    $ILMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $ALNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alnylam Pharma upgraded by Wolfe Research

    Wolfe Research upgraded Alnylam Pharma from Underperform to Peer Perform

    8/4/25 8:14:44 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharma upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Alnylam Pharma from Perform to Outperform and set a new price target of $490.00

    8/4/25 8:14:34 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Alnylam Pharma with a new price target

    Raymond James resumed coverage of Alnylam Pharma with a rating of Outperform and set a new price target of $370.00

    7/30/25 7:32:36 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

    4/30/24 1:44:03 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OXLUMO issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-4) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 09/19/2023. Application Category: NDA, Application Number: 214103, Application Classification: Labeling

    9/20/23 2:36:38 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for AMVUTTRA issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (SUPPL-2) with active ingredient VUTRISIRAN has changed to 'Approval' on 02/16/2023. Application Category: NDA, Application Number: 215515, Application Classification: Labeling

    2/17/23 12:30:09 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Supran Bryan

    3 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    9/22/25 4:04:24 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Reitan Colleen F exercised 18,000 shares at a strike of $100.65 and sold $8,416,730 worth of shares (18,000 units at $467.60) (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    9/11/25 4:05:55 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Commercial Officer Tanguler Tolga sold $1,557,649 worth of shares (3,474 units at $448.37), decreasing direct ownership by 12% to 25,992 units (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    9/2/25 4:10:42 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    SEC Filings

    View All

    Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    9/12/25 5:17:52 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Alnylam Pharmaceuticals Inc.

    8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    9/10/25 7:30:33 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Alnylam Pharmaceuticals Inc.

    10-Q - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    7/31/25 8:11:22 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Reitan Colleen F bought $10,363 worth of shares (36 units at $287.85), sold $8,383 worth of shares (36 units at $232.86) and was granted 775 shares (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    5/12/25 4:05:00 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Financials

    Live finance-specific insights

    View All

    Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

    − Generated Q2 2025 Total Net Product Revenues of $672 Million (64% Growth Compared with Q2 2024), Driven Primarily by Total TTR Revenues of $544 Million (77% Growth Compared with Q2 2024) – − Achieved Approximately 1,400 ATTR-CM Patients on AMVUTTRA® (vutrisiran) as of June 30, 2025 – − Obtained Approvals for AMVUTTRA for the Treatment of ATTR-CM in the European Union, Brazil, the United Kingdom and Japan – − Initiated TRITON-CM Phase 3 Trial of Nucresiran in Patients with Wild-Type or Hereditary ATTR-CM – − Raises 2025 Guidance for TTR Franchise Net Revenues to $2,175 Million to $2,275 Million; Total Net Product Revenues to $2,650 Million to $2,800 Million, Representing a $575 Mil

    7/31/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2025 on Thursday, July 31, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2025 results as well as expectations for the future via conference call on Thursday, July 31, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Pharmaceuti

    7/17/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

    − Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28% Year-Over-Year Growth Compared to Q1 2024 Driven by Continued Strong Growth of 36% from hATTR-PN Franchise – − Received U.S. Food and Drug Administration (FDA) Approval of AMVUTTRA® (vutrisiran) to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) – − AMVUTTRA ATTR-CM Launch Underway with Strong Progress Across All Early Commercial Indicators – − Approval of Qfitlia™ Represents the First and Only Therapeutic to Treat Hemophilia A or B With or Without Inhibitors and the Sixth Alnylam-Discovered

    5/1/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Leadership Updates

    Live Leadership Updates

    View All

    Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

    Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD). Alnylam, a pioneer in RNA interference (RNAi) therapeutics, will utilize the AGD clinical genomic database to derive real-world insights and accelerate drug target discovery.

    9/18/25 9:15:00 AM ET
    $ALNY
    $ILMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. "Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam's founding and the development of a transformative new class of medicines," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "He has provided invaluable guidance over the past twenty-two years that has

    3/5/25 7:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category

    As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on the boards of several biotech and pharmaceutical companies; This marks ByHeart's first non-executive Board chair appointment In addition to Schulman, ByHeart appoints Niall Mullane, PhD, as Chief Quality Officer to join the experienced executive team; Mullane brings 15 years of quality and food safety experience in the infant nutrition category NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of th

    3/5/24 9:06:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    11/12/24 9:50:12 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    11/8/24 10:34:33 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    8/12/24 9:40:06 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care